BR0207061A - Composição e método para o tratamento de lúpus e de doenças inflamatórias das articulações - Google Patents

Composição e método para o tratamento de lúpus e de doenças inflamatórias das articulações

Info

Publication number
BR0207061A
BR0207061A BR0207061-8A BR0207061A BR0207061A BR 0207061 A BR0207061 A BR 0207061A BR 0207061 A BR0207061 A BR 0207061A BR 0207061 A BR0207061 A BR 0207061A
Authority
BR
Brazil
Prior art keywords
composition
lupus
treatment
bromelain
quercetin
Prior art date
Application number
BR0207061-8A
Other languages
English (en)
Inventor
Randy H Ziegler
Original Assignee
Randy H Ziegler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Randy H Ziegler filed Critical Randy H Ziegler
Publication of BR0207061A publication Critical patent/BR0207061A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"COMPOSIçãO E MéTODO PARA O TRATAMENTO DE LúPUS E DE DOENçAS INFLAMATóRIAS DAS ARTICULAçõES". Uma composição e um método para a melhora do lúpus relacionado a doenças reumáticas e doenças inflamatórias das articulações. A composição consiste de um bioflavonóide combinado com Bromelaína. A vitamina C pode ser adicionada à composição para melhorar sua eficácia. O flavonóide preferido é a Luteolina ou a Quercetina. A Miricetina também pode ser usada, como pode ser um glicosídeo tal como a Rutina que contém ou Luteolina, Quercetina ou Miricetina, como uma aglicona. Outros flavonóides eficazes podem ser selecionados por sua capacidade para interagir com o canal Kv1.3 de linfócitos. No método preferido de tratamento uma mistura de flavonóide, Bromelaina e Vitamina C é administrada pelo menos diariamente por uma via oral. Uma mistura de 500 mg de Quercetina, 500 mg de Bromelaína e 500 mg de Vitamina C administrada três vezes por dia é eficaz.
BR0207061-8A 2001-12-07 2002-12-09 Composição e método para o tratamento de lúpus e de doenças inflamatórias das articulações BR0207061A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33919901P 2001-12-07 2001-12-07
PCT/US2002/039297 WO2003049725A2 (en) 2001-12-07 2002-12-09 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases

Publications (1)

Publication Number Publication Date
BR0207061A true BR0207061A (pt) 2004-02-17

Family

ID=23327940

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207061-8A BR0207061A (pt) 2001-12-07 2002-12-09 Composição e método para o tratamento de lúpus e de doenças inflamatórias das articulações

Country Status (8)

Country Link
US (1) US20040248821A1 (pt)
EP (1) EP1450835B1 (pt)
CN (1) CN1606448A (pt)
AT (1) ATE339962T1 (pt)
AU (1) AU2002366645A1 (pt)
BR (1) BR0207061A (pt)
DE (1) DE60214881T2 (pt)
WO (1) WO2003049725A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10321725A1 (de) * 2003-05-14 2004-12-02 Mucos Pharma Gmbh & Co Enzymhaltige Zusammensetzungen, daraus hergestellte diätetische Lebensmittel und Arzneimittel und ihre Verwendung für medizinische Zwecke
CN1327834C (zh) * 2004-10-12 2007-07-25 中国药科大学 防治皮肤瘙痒症的药物组合物
US20090182003A1 (en) * 2006-01-13 2009-07-16 President And Fellows Of Harvard College Methods and Compositions for Treatment Cell Proliferative Disorders
US10376550B2 (en) 2007-12-12 2019-08-13 Dacy Tech Pty Ltd. Nutraceutical composition and methods of use
KR101564056B1 (ko) * 2007-12-12 2015-10-28 데이씨 테크 피티와이 리미티드 기능식품 조성물 및 용도 방법
ES2487513T3 (es) * 2007-12-12 2014-08-21 Dacy Tech Pty Ltd Composición nutracéutica y métodos de uso
DK2321640T3 (en) * 2008-08-21 2017-02-27 Immunogenics Llc FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS
WO2010075611A1 (en) * 2009-01-05 2010-07-08 Bio - Enhancements Pty Ltd Composition comprising proanthocyanidin, proteolytic enzyme and aloe vera/agave species substance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19957318A1 (de) * 1999-11-29 2001-06-21 Mucos Pharma Gmbh & Co Beeinflussung von TGF-Beta durch Proteolytische Enzyme
WO2002007768A1 (en) * 2000-07-20 2002-01-31 Pitman Bradford D Dietary supplement compositions

Also Published As

Publication number Publication date
WO2003049725A2 (en) 2003-06-19
CN1606448A (zh) 2005-04-13
DE60214881T2 (de) 2007-05-03
AU2002366645A8 (en) 2003-06-23
WO2003049725A3 (en) 2003-10-02
AU2002366645A1 (en) 2003-06-23
EP1450835B1 (en) 2006-09-20
DE60214881D1 (de) 2006-11-02
ATE339962T1 (de) 2006-10-15
EP1450835A2 (en) 2004-09-01
US20040248821A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BR0109912A (pt) Novas combinações antelmìnticas
BR0208103A (pt) Composição para a prevenção de osteoporose compreendendo uma combinação de isoflavonas e ácidos graxos poliinsaturados
HK1075617A1 (en) Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
PT979244E (pt) Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
NZ504986A (en) Erythromycin and azalide derivatives and pharmaceutical compositions thereof, useful as antibacterial agents and antoprotozoa agents
DE60123277D1 (de) Makrolidantibiotika
BR0111210A (pt) Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias
BR0316776A (pt) Formula para anti-infeccioso tópico
ES2723779T3 (es) Formulación para el control de piojos y garrapatas en el ganado
AR034343A1 (es) Combinaciones farmaceuticas
BR0207061A (pt) Composição e método para o tratamento de lúpus e de doenças inflamatórias das articulações
BR0306306A (pt) Composição contendo extrato de matricária e uso desta
IS6559A (is) Notkun á azalíð sýklalyfssamsetningum til að meðhöndla eða fyrirbyggja bakteríu- eða frumdýrasýkingu í spendýrum
BR0208695A (pt) Composições e métodos para a prevenção e tratamento de c ncer humano da próstata
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BRPI0418854A (pt) composições herbáceas
BR0107701A (pt) Produtos alimentìcios e processos
AR013411A1 (es) Composicion de aplicacion para tratamientos antivirales y afecciones micosicas y/o bacterianas y utilizacion de dichas composiciones.
BR0109589A (pt) Derivados de pirano[2,3-c]imidazo[-1,2-a]piridina para o tratamento de distúrbios gastrointestinais
TR200101344T2 (tr) Propionil L-karnitinden ve bir flavonoid'den oluşan antioksidan bileşim
BR0204228A (pt) Métodos para melhorar os sintomas de uma psicose e de esquizofrenia e para triar moléculas de teste, e, composto orgânico
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
BR9807444A (pt) Produto antimicrobial
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.